Short answer
Relay Therapeutics, Inc. (RLAY) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$74M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$74M
- +15.8% YoY · −5.4% QoQ
- EPS (diluted)
- −$0.43
- +30.6% YoY · −4.9% QoQ
Source: XBRL data from the Relay Therapeutics, Inc. (RLAY) Q3 2025 10-Q on SEC EDGAR. USD.
Relay Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical trial collaboration with Pfizer for combination therapy in metastatic breast cancer, initiated June 2024, introducing additional regulatory and safety risks
- Increased risk of clinical trial delays from FDA potentially requiring additional trials or changing approval conditions due to novel mechanisms of action
- FDA may require companion diagnostics for RLY-2608 biomarker-defined population, failure of third-party diagnostics could delay regulatory approval
- Near-term risk of slower patient enrollment due to competitive clinical trial environment and specific eligibility criteria, impacting trial timelines
- Financial risk from increased costs if clinical trials face delays, with potential impact on exclusive commercialization period and competitive positioning
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Relay Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.